BUSINESS
    Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
    By Shinya Sato April 23, 2026
    Genmab is aiming to bring two new cancer drugs to market in the US in 2027, as it looks to accelerate growth through late-stage pipeline assets, with launches in other markets, including Japan, to follow,…

    LATEST

    Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
    April 23, 2026
    Quick Look:Bayer Japan aims to continue growing Kerendia, Nubeqa, and Eylea 8 mg after the three key brands logged double- or triple-digit gains in 2025.Approval-pending sevabertinib is set for a 2026 launch, with two more…
    JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
    April 23, 2026
    The Japan Pharmaceutical Manufacturers Association (JPMA) has pressed for a “freeze” on price cuts for patent-protected medicines, citing growing concerns over Japan’s competitiveness in the global drug market.Speaking at a policy study group meeting of…
    APAC Disbands Drug Discovery WG as Asia Capabilities Rise
    April 23, 2026
    The Asia Partnership Conference of Pharmaceutical Associations (APAC) has decided to disband its long-running drug discovery alliance working group, reflecting shifting regional dynamics as Asian countries strengthen their own R&D capabilities.The “Drug Discovery Alliance Expert…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

    Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

    COLUMN

    The Patient North Star: How Gilead Japan Redefined Innovation
    By Philip Carrigan

    In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…

    COMMENTARY

    Challenges in a Post-AG Era: Ensuring a Reliable Supply System
    By Tatsuya Otsuka

    Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA